Mirion Technologies, Inc. (MIR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session indicate positive sentiment: increased guidance for 2025, strong nuclear and medical segment outlooks, and strategic partnerships. Despite some uncertainties in timing and specifics, the overall confidence in market opportunities, especially in nuclear power and SMR projects, is evident. The raised guidance and strategic acquisitions further support a positive outlook. Given the market cap, a 2% to 8% stock price increase is expected.
Key Financial Performance
Third quarter revenue $223 million, a nearly 8% increase from last year's third quarter. On an organic basis, revenue grew 4.7%, reflecting mid-single-digit organic growth from both segments. The nuclear power end market organic revenue grew 9% in the quarter and 11% year-to-date. The increase is attributed to strong performance in the nuclear power end market.
Adjusted EBITDA $52.4 million, up 14.7% versus third quarter last year. Both the Nuclear and Safety and Medical segments contributed to the increase in both dollars and margin expansion. The increase is due to greater volumes, net price inflation, and procurement initiatives.
Blended cost of debt 2.8% expected for year-end 2025, reflecting a 460 basis point improvement over the past year. This improvement is due to actions taken to diversify the capital structure and reduce interest expense.
Third quarter adjusted free cash flow $18 million, contributing to $53 million of year-to-date adjusted free cash flow. The improvement is attributed to adjusted EBITDA growth, lower interest expense, and lower CapEx, partially offset by a use of cash from net working capital.
Q3 adjusted orders Increased 2.4%. Nuclear power end markets orders grew double digits in the quarter. The increase excludes the impact of the Turkey debooking in last year's third quarter and reflects growth across key verticals like new builds and SMRs.
Third quarter nuclear power adjusted orders Grew 21% or 16% excluding foreign exchange tailwinds, reflecting growth across each key vertical, including new builds, SMRs, and the installed base.
Third quarter nuclear power-related organic revenue Grew 9% in the quarter compared to 4.4% for the Collective Nuclear and Safety segment. The growth is attributed to strong performance in the nuclear power end market.
Adjusted EPS $0.12 per share, a 50% increase versus the third quarter of last year. The increase is due to growing EBITDA, tax projects, and lower net interest costs.
Nuclear and Safety segment revenue $144.6 million, up 9% or $11.9 million. Organic growth for the segment was 4.4%, driven by nuclear power end market growth of 9% and defense and diversified end market growth of 7%.
Medical segment revenue $78.5 million, up 5.9% or $4.4 million. Organic revenue grew 5.2%, driven by growth in dosimetry services and favorable mix.
Medical segment adjusted EBITDA $28.2 million, nearly 10% better than last year. Margins improved by 120 basis points to 35.9%, reflecting healthy operating leverage and favorable mix.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
InstadoseVUE digital dosimeters: Introduced in late 2023, showing strong adoption with 7% organic revenue growth in dosimetry services.
Nuclear power end market: Organic revenue grew 9% in Q3 and 11% year-to-date. Orders grew 21% in Q3, with $17 million in SMR-related orders. Year-to-date SMR orders totaled $26 million, up from $17 million in prior years.
Medical segment: Mid-single-digit organic growth in Q3, with 5.2% growth year-to-date. Strategic alignment with cancer care revolution, with 75% of revenue from this market.
Adjusted EBITDA: Increased 14.7% to $52.4 million in Q3, with margin expansion of 140 basis points. Year-to-date adjusted free cash flow reached $53 million.
Cost of debt: Blended cost of debt reduced to 2.8%, reflecting a 460 basis point improvement over the past year.
Acquisitions: Acquired Certrec and announced Paragon Energy Solutions acquisition to broaden nuclear power portfolio and enhance U.S. presence.
Nuclear super cycle: Positioned to benefit from global nuclear growth, with significant support for new builds and SMRs, including U.S. government initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
U.S. healthcare environment: The current U.S. healthcare environment is pressuring the U.S. RTQA business, leading to delays in customer activity. The timing and magnitude of a rebound remain uncertain due to government shutdown headwinds.
U.S. Department of Energy demand: Demand from the U.S. Department of Energy has been muted since the launch of DOGE and the government shutdown, impacting the Labs and Research end market.
China laboratory instruments demand: Order flow from China for laboratory instruments has slowed, attributed to changing funding and trade dynamics. This is seen as a transitory issue but poses short-term challenges.
U.S. government-related projects: A large portion of U.S. government-related projects has been pushed to 2026 due to the government shutdown, delaying revenue recognition and impacting the opportunity pipeline.
RTQA hardware orders: RTQA hardware orders in the U.S., China, and Japan were down in the quarter, reflecting changing funding and trade dynamics. This is expected to normalize but currently affects revenue.
Funding strain in Labs and Research market: Signs of funding strain in the Labs and Research market are evident, impacting order flow and creating uncertainty in demand.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Adjusted Free Cash Flow: Expected to be between $100 million and $115 million, with a conversion rate of 45% to 49% of adjusted EBITDA. This is a significant improvement compared to 2024's conversion of 32%.
Blended Cost of Debt: Expected to remain at 2.8% into 2026, reflecting a 460 basis point improvement over the past year.
Nuclear Power End Market Growth: Year-to-date organic revenue growth is on track for double-digit growth in 2025. Orders in this segment grew 21% in Q3, with SMR-related orders totaling $26 million year-to-date.
Large Opportunity Pipeline: $285 million worth of opportunities remain, with $175 million expected to be awarded by year-end 2025 and the remaining $110 million likely in 2026.
Medical Segment Growth: On track for mid-single-digit organic growth for 2025. Margins are expected to expand in Q4, though not at the same levels as earlier in the year.
Nuclear Super Cycle: The company believes it is in the early stages of a nuclear super cycle, supported by global trends and increased nuclear capacity forecasts.
Paragon Energy Solutions Acquisition: Expected to close by year-end 2025, broadening Mirion's U.S. presence and adding products, software, and services to its portfolio.
Certrec Acquisition: Enhances Mirion's software solutions with regulatory compliance tools, aiding in life extensions for existing facilities and applications for new builds and SMRs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Should we focus on the commercial nuclear backlog, and is there an expectation of material acceleration in that backlog?
A:Management highlighted three drivers for the nuclear market: increased capacity utilization of reactors, acceleration in global utility-scale projects, and the growing viability of SMR projects. They expect the nuclear power-related backlog to grow over time, but timing is difficult to predict. The flow business, which is not visible in the backlog, is also a significant driver.
Q:How is the medical business performing in the current environment, and is there visibility to normalization of spend?
A:Management expressed confidence in the medical business, citing strong demand drivers such as aging populations and increased cancer incidence. They expect equilibrium in the RTQA business soon and noted strong growth in nuclear medicine and medical dosimetry. However, they anticipate flattish revenue in Q4 due to tough comparisons.
Q:What is the confidence level in the $175 million pipeline being awarded?
A:Management expressed confidence in the pipeline, noting that timing is unpredictable but conviction is improving. They believe they have a strong right to win in the opportunity set.
Q:Why can't there be a quarter with orders above $300 million?
A:Management believes it is possible to see strong double-digit order growth in Q4, potentially exceeding $300 million.
Q:What is the opportunity in the SMR market, and how should the $10 million project be interpreted?
A:Management noted over 120 SMR projects globally, with many in early development stages. They expect a shakeout and consolidation in the market. The $10 million project is part of a broader opportunity, and they are positioning themselves as a critical partner in the SMR ecosystem. They also booked an additional $5.5 million SMR-related order recently.
Q:How does the backlog conversion metric look exiting FY25, and does the $175 million in large orders influence this metric?
A:Management expects the next 12 months' revenue coverage to remain between 45% and 50%. The $175 million in large orders will contribute revenue over multiple years, with smaller portions in the first year and ramping up in subsequent years.
Q:How does the Westinghouse partnership work on new builds, and what is Paragon's role?
A:Management emphasized their strong historical relationship with Westinghouse and the potential for increased relevance with the Paragon acquisition. They expect their positioning for new build activity to improve.
Q:What factors could accelerate or delay SMR project awards?
A:Factors include deal negotiations, approvals, and the holiday season. Management is disciplined on margins and cash profiles. They noted government support and funding as accelerators for the SMR market.
Q:What steps are being taken to secure talent and strengthen supply chains?
A:Management highlighted talent acquisition through recent M&A and strong retention dynamics. They are conservative in managing supply chain risks, securing critical commodities upfront, and diversifying suppliers.
Q:How is pricing power holding up, and is it different between nuclear safety and medical?
A:Management reported positive pricing dynamics, with $2 million in price/cost benefits in Q3. They are less aggressive on pricing in the U.S. medical market compared to other segments.
Q:What is driving the U.S. healthcare environment, and how does it impact the medical business?
A:Cuts in Medicaid and overall noise in the U.S. healthcare system are creating a defensive CapEx footing. However, demand dynamics remain unchanged, and management expects equilibrium to be achieved.
Q:What is the economic contribution of building a nuclear reactor to Mirion?
A:Management cited historical examples, such as $80-$90 million in backlog for a two-reactor project. They expect the front-end opportunity to increase with recent acquisitions but reserved specific numbers for future updates.
Q:Is the $1 per megawatt revenue opportunity still a good proxy, and how do recent acquisitions impact this?
A:Management believes the $1 per megawatt proxy will increase over time, especially in the SMR market, where premiums are higher. They plan to provide an update in early 2024.
Q:Do larger one-time orders have a different margin profile?
A:Management is committed to a 30% EBITDA margin target. While new builds have lower margins than installed base work, they are not moving off their margin commitment.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers or timelines for several questions, such as the exact economic contribution of nuclear reactor builds, the updated $1 per megawatt revenue proxy, and the detailed impact of recent acquisitions on these metrics. They also used vague language when discussing the timing of backlog growth and SMR market evolution.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Santee
Africa level
Asset completion
Association headline
Brookfield Asset
CEO CFO
Certrec
Founder
Google
Group President
Medical Group
Monday
Nuclear Safety
Panel
Paragon
Recall
SMR order
South
application
build SMRs
care
conversion
cost debt
date power
end market
facility
flow date
interest
market progress
offering
order SMR
power end
power portfolio
safety
segment date
software service
track
MIR Transcript
Mirion Technologies, Inc. (MIR) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary shows strong financial performance with a 10% revenue increase, improved gross margins, and significant growth in operating and net income. Free cash flow also increased substantially. Although there was no discussion on strategic initiatives or risks, the financial metrics are robust enough to predict a positive stock price movement. The market cap indicates moderate volatility, supporting a positive outlook.
Mirion Technologies, Inc. (MIR) Presents at Citi's Global Industrial Tech & Mobility Conference 2026 Transcript
Neutral2-18
Mirion Technologies, Inc. (MIR) Q4 2025 Earnings Call Transcript
Positive2-11
The earnings call highlighted strong financial metrics, optimistic guidance, and strategic acquisitions, particularly in the nuclear sector. The company's focus on AI and digital strategies, along with a positive outlook for 2025 and beyond, supports a positive sentiment. While some uncertainties remain, such as specific win rates and AI KPIs, the overall narrative is growth-oriented, with significant opportunities in nuclear power and medicine. Given the mid-cap status, the market is likely to react positively, but not excessively, resulting in a positive prediction of 2% to 8% stock price increase.
Mirion Technologies, Inc. (MIR) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call summary and Q&A session indicate positive sentiment: increased guidance for 2025, strong nuclear and medical segment outlooks, and strategic partnerships. Despite some uncertainties in timing and specifics, the overall confidence in market opportunities, especially in nuclear power and SMR projects, is evident. The raised guidance and strategic acquisitions further support a positive outlook. Given the market cap, a 2% to 8% stock price increase is expected.
MIR Slides
MIR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
